Cytodyn OTC Stock Quote Today

CYDY
 Stock
  

USD 0.41  0.01  2.38%   

Market Performance
4 of 100
Odds Of Distress
Over 52
Cytodyn is trading at 0.41 as of the 3rd of October 2022; that is -2.38% down since the beginning of the trading day. The stock's open price was 0.42. Cytodyn has 52 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Cytodyn are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of August 2022 and ending today, the 3rd of October 2022. Click here to learn more.
CytoDyn Inc. operates as a late-stage biotechnology company. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Cytodyn operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 24 people. The company has 660.19 M outstanding shares. More on Cytodyn
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Cytodyn OTC Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cytodyn's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cytodyn or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Cytodyn is way too risky over 90 days horizon
Cytodyn has some characteristics of a very speculative penny stock
Cytodyn appears to be risky and price may revert if volatility continues
Cytodyn has high likelihood to experience some financial distress in the next 2 years
The company currently holds 36.24 M in liabilities. Cytodyn has a current ratio of 0.78, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cytodyn until it has trouble settling it off, either with new capital or with free cash flow. So, Cytodyn's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cytodyn sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cytodyn to invest in growth at high rates of return. When we think about Cytodyn's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 266 K. Net Loss for the year was (143.6 M) with profit before overhead, payroll, taxes, and interest of 0.
Cytodyn currently holds about 1.36 M in cash with (104.48 M) of positive cash flow from operations.
Latest headline from www.fiercebiotech.com: Aligos demands jury trial to settle Janssen theft allegations, files fraud counterclaims - FierceBiotech
CEO and President and DirectorNader Pourhassan
Average Analyst Recommendation
Analysts covering Cytodyn report their recommendations after researching Cytodyn's financial statements, talking to executives and customers, or listening in on Cytodyn's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Cytodyn. The Cytodyn consensus assessment is calculated by taking the average forecast from all of the analysts covering Cytodyn.
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Cytodyn's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cytodyn [CYDY] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Small-Cap' category with current market capitalization of 283.88 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cytodyn's market, we take the total number of its shares issued and multiply it by Cytodyn's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Cytodyn conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 660.19 M outstanding shares. Cytodyn currently holds about 1.36 M in cash with (104.48 M) of positive cash flow from operations.
Check Cytodyn Probability Of Bankruptcy
Ownership
Cytodyn retains a total of 660.19 Million outstanding shares. Cytodyn shows 8.1 percent if its outstanding shares held by insiders and 8.1 percent owned by other corporate entities . Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Cytodyn Ownership Details

Cytodyn Stock Price Odds Analysis

Based on a normal probability distribution, the odds of Cytodyn jumping above the current price in 90 days from now is about 87.83%. The Cytodyn probability density function shows the probability of Cytodyn otc stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the otc stock has a beta coefficient of 1.4696 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Cytodyn will likely underperform. Additionally, the company has an alpha of 0.5126, implying that it can generate a 0.51 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 0.41HorizonTargetOdds Above 0.41
12.13%90 days
 0.41 
87.83%
Based on a normal probability distribution, the odds of Cytodyn to move above the current price in 90 days from now is about 87.83 (This Cytodyn probability density function shows the probability of Cytodyn OTC Stock to fall within a particular range of prices over 90 days) .

Cytodyn Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Cytodyn that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cytodyn's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cytodyn's value.
InstituionSecurity TypeTotal SharesValue
Firsthand Capital Management IncCommon Shares222.7 K94 K
L S Advisors IncCommon Shares50.5 K21 K
View Cytodyn Diagnostics

Cytodyn Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Cytodyn market risk premium is the additional return an investor will receive from holding Cytodyn long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cytodyn. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Cytodyn's alpha and beta are two of the key measurements used to evaluate Cytodyn's performance over the market, the standard measures of volatility play an important role as well.

Cytodyn Stock Against Markets

Picking the right benchmark for Cytodyn otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Cytodyn otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Cytodyn is critical whether you are bullish or bearish towards Cytodyn at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cytodyn without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bond Directory Now

   

Bond Directory

Find actively traded corporate debentures issued by US companies
All  Next Launch Module

Cytodyn Corporate Directors

Cytodyn corporate directors refer to members of a Cytodyn board of directors. The board of directors generally takes responsibility for the Cytodyn's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Cytodyn's board members must vote for the resolution. The Cytodyn board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Carl Dockery - DirectorProfile
Bruce Montgomery - Independent DirectorProfile
David Welch - DirectorProfile
Jordan Naydenov - Independent DirectorProfile

Invested in Cytodyn?

The danger of trading Cytodyn is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Cytodyn is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Cytodyn. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Cytodyn is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. Note that the Cytodyn information on this page should be used as a complementary analysis to other Cytodyn's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for Cytodyn OTC Stock analysis

When running Cytodyn price analysis, check to measure Cytodyn's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytodyn is operating at the current time. Most of Cytodyn's value examination focuses on studying past and present price action to predict the probability of Cytodyn's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytodyn's price. Additionally, you may evaluate how the addition of Cytodyn to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Is Cytodyn's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytodyn. If investors know Cytodyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytodyn listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cytodyn is measured differently than its book value, which is the value of Cytodyn that is recorded on the company's balance sheet. Investors also form their own opinion of Cytodyn's value that differs from its market value or its book value, called intrinsic value, which is Cytodyn's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytodyn's market value can be influenced by many factors that don't directly affect Cytodyn's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytodyn's value and its price as these two are different measures arrived at by different means. Investors typically determine Cytodyn value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytodyn's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.